A Treatment Option That Adds Convenience For Patients
- The Food and Drug Administration approved a new all-oral, chemotherapy-free combination (acalabrutinib + venetoclax) for people with newly diagnosed CLL.
- The treatment is fixed-duration, meaning it is taken for about 14 months and then stopped if the disease is controlled.
- In clinical trials, many patients went years without their CLL getting worse, which translates to the possibility of meaningful time off therapy.
- Careful monitoring is still needed, especially early in treatment, but no routine infusion center visits are required as the medications can be taken at home.
“This becomes another preferred frontline treatment,” Dr. Catherine Deifenbach, a hematologist/oncologist at NYU Langone, tells SurvivorNet. “The time-limited approach is a major advance, because prior frontline BTK regimens used indefinite treatment.”
Read MoreWhat’s Different About This Treatment?
The new regimen combines two targeted medicines that work in different ways to stop CLL cells from surviving and multiplying. Unlike chemotherapy, these drugs are designed to focus on specific pathways that cancer cells use to grow. In the AMPLIFY clinical trial, people who received acalabrutinib plus venetoclax had better control of their disease than those who received standard chemoimmunotherapy. At four years of follow-up, the average time before the disease worsened had not yet been reached, and fewer than half of patients had needed additional treatment.“CLL is generally a slow-growing disease, but it is encouraging that the median time before progression was not reached at four years,” Dr. Deifenbach explains.
Another benefit of the treatment combination is that it is “fixed duration,” which means treatment is given for a set amount of time — in this case, about 14 months. Patients who respond well can then stop therapy and be followed closely with regular checkups.
Acalabrutinib + Venetoclax: What To Expect
Because both medicines are taken by mouth, this option may be especially appealing for people who live far from treatment centers or want to limit clinic visits, Dr. Deifenbach says.
It’s important to know that venetoclax is started gradually with a careful dose ramp-up and regular blood tests to reduce the risk of a complication called tumor lysis syndrome. Your healthcare team will guide you closely during this phase.
The most common side effects associated with this treatment combination include:
- Low white blood cell counts (neutropenia)
- Infections
- Headache
- Diarrhea
- Muscle or joint pain
- Fatigue
Acalabrutinib can also increase the risk of heart rhythm problems and bleeding in some people.
Not every treatment is right for every patient. Doctors consider other health conditions — such as heart disease, prior cancers, or use of blood thinners — when recommending treatment options.
Overall, this approval gives people with newly diagnosed CLL another effective, chemotherapy-free option that offers the possibility of time off treatment. Patients should talk with their healthcare team about whether this approach fits their medical history, lifestyle, and personal preferences.
Questions To Ask Your Doctor
- Am I eligible for acalabrutinib plus venetoclax?
- What should I expect after 14 months of treatment?
- How often will I need blood tests or clinic visits during the venetoclax ramp-up period?
- What side effects should I watch for?
- How does this option compare to others like continuous BTK therapy?
Learn more about SurvivorNet's rigorous medical review process.
